Allan Reine
Board Member
Prime Medicine, Inc. (PRME)Equibles does not estimate personal net worth.
Get an email with a short summary when Prime Medicine, Inc. publishes a filing, an earnings call transcript or a press release.
Get PRME alertsAbout Allan Reine
Allan Reine is recorded as CEO and Board Member at Prime Medicine, Inc. (PRME). The newest filing on record that lists Allan Reine as CEO and Board Member at Prime Medicine, Inc. (PRME) is dated April 23, 2026. Earlier roles on record: CFO at Foghorn Therapeutics Inc. (FHTX) until January 16, 2024. Prime Medicine, Inc. reported in an 8-K filed January 5, 2024 that Allan Reine was appointed Chief Financial Officer and the principal financial officer, effective January 17, 2024. Foghorn Therapeutics Inc. reported in an 8-K filed January 3, 2024 that Allan Reine resigned as Chief Financial Officer, effective January 16, 2024. The proxy statement of Prime Medicine, Inc. reports total compensation of $3,894,187 for Allan Reine in fiscal 2025, including a base salary of $606,212. Disclosed compensation is on record for 5 fiscal years. Prime Medicine, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Prime Medicine, Inc. includes Allan Reine, M.D. (CEO and Board Member), Jeffrey Marrazzo (Chairman), Svetlana Makhni (CFO) and 2 others.
“On January 4, 2024, the Board of Directors (the "Board") of Prime Medicine, Inc. (the "Company") appointed Allan Reine as the Chief Financial Officer and the principal financial officer of the Company effective as of January 17, 2024.”
“On December 29, 2023, Allan Reine, M.D. notified Foghorn Therapeutics Inc. (the "Company") of his decision to resign as Chief Financial Officer, effective January 16, 2024, to pursue other opportunities.”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 23, 2026
-
Current
Start not stated–present
Last confirmed April 23, 2026
-
Start not stated–2025-04-22
Last confirmed by a filing; no departure on record
-
Start not stated–2024-01-16
Company network
Leadership on record at Prime Medicine, Inc.
- Allan Reine, M.D. CEO, Board Member
- Jeffrey Marrazzo Chairman
- Svetlana Makhni CFO
- Svetlana N. Makhni CFO
- Jeff Marrazzo Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Prime Medicine, Inc. (PRME) | Chief Executive Officer | $606,212 | $3,894,187 |
| 2024 | Prime Medicine, Inc. (PRME) | Chief Financial Officer | $479,489 | $4,623,802 |
| 2023 | Prime Medicine, Inc. (PRME) | Chief Financial Officer | — | — |
| 2022 | Foghorn Therapeutics Inc. (FHTX) | Chief Financial Officer | $435,000 | $1,987,269 |
| 2021 | Foghorn Therapeutics Inc. (FHTX) | Chief Financial Officer | $416,000 | $2,014,346 |